Clinical Observation of Bevacizumab in the Treatment of Diabetic Macular Edema

Abstract

Abstract:

Objective: To evaluate the clinical effect and safety of intravitreal injection of bevacizumab in the treatment of diabetic
macular edema. Methods: The records of 26 eyes of 22 patients treated with intravitreal injection of 1.75mg bevacizumab for diabetic
macular edema were retrospectively analyzed. Best corrected visual acuity（BCVA）, intraocular pressure, choroidal leaks, central
retinal thickness（CFT） 1, 2, 3 months and 6 months before and after the treatment were analyzed and compared. Follow- up
observation were carried out among all cases after 6 months. Results: 26 eyes of 22 patients with the average of（57±18.56）years old
were included. The mean baseline of BCVA, CFT were（logMAR 0.82±0.63）,（624.2±176.1）μm respectively. Although there was no
significant decrease in mean CFT one week after the injection, the mean BCVA had significant improvement. At the last visit of 9.8
months' follow up, BCVA and CFT showed significant improvements over baseline values, which had a significant difference（P<
0.001）. BCVA was improved by at least two lines in 22 eyes（84.6%）, remained stable in 2 eyes（7.7%）at the last visit. A total of 92
injections were performed and the average number of injections was（3.98±1.52）in the group. Conclusion: Intravitreal injection of
bevacizumab can improve the visual acuity, reduce macular edema and choroidal leakage in patients with diabetic macular edema.
Repeated treatment has better effect, but a prolonged treatment effect needs further observation.

Key words: bevacizumab（avastin）, diabetic retinopathy, macular edema, intravitreal injection

CLC Number:

R774.1

Duan Zhiguang, Jia Yunqin, Mo Ni, Yu Liyun, Chen Yingchao, Liu Min, Pu Shixue, Z. Clinical Observation of Bevacizumab in the Treatment of Diabetic Macular Edema[J]. J4, 2016, 1(4): 55-59.

References

〔1〕NGUYEN Q D，SHAH S M，VAN ANDEN E，et al. Supple?
mental oxygen improves diabetic macular edema：a pilot
study〔J〕. Invest Ophthalmol Vis Sci，2004，45：617-624.
〔2〕FERRARA N. Vascular endothelial growth factor：basic sci?
ence and clinical progress〔J〕. Endocr Rev，2004，25：581-
611.
〔3〕VALMAGGIA C，HAUETER I，KLOOS P，et al. The treat?
ment of choroidal neovascularizations in age-related macu?
lar degeneration using either Avastin or Lucentis〔J〕. Klin
Monatsbl Augenheilkd，2009，226（4）：294-298.
〔4〕于同利，毕宏生. Avastin 在眼科应用的研究进展〔J〕.
国际眼科杂志，2008，8（4）：810-812.
〔5〕STEWART M W. The expanding mle of vascular endotheli?
al growth factor inhibitors in ophthalmology〔J〕. Mayo Clin
Proc，2012，87：77-88．
〔6〕TERUI T，KONDO M，SUGITA T，et al.Changes in areas of
capillary nonperfusion after intravitreal injection of beva?
cizumab in eyes with branch retinal vein occlusion〔J〕.
Retina，2011，31：1068-1074．
〔7〕THAPA R，POUDYA J G. Short term results of intravitreal
bevacizumab for the treatment of macular edema secondary
to retinal vein occIusion〔J〕. Nepal J Ophthalmol，2013，5：
63-68.
〔8〕EPSTEIN D I，ALGVERE P V，VON WENDT G，et al.
Bevacizumab for macular edema in central retinal vein oc?
clusion：a prospective，randomized，double-masked clinical
study〔J〕. Ophthalmology，2012，119：1184-1189．

〔9〕MARNEROS A G，FAN J，YOKOYAMA Y，et al. Vascular
endothelial growth factor expression in the retinal pigment
epithelium is essential for choricapillaris development and
visualfunction.Am〔J〕.Ophthalmol，2005，167：1451-1459.
〔10〕SIEGEL R A，DREZNIK A，MB K，et al. Intravitreal Beva?
cizumab Treatment for Macular Edema due to Branch Ret?
inal Vein occlusion in a Clinical Setting〔J〕. Curr Eye Res，
2012，37：823-829．
〔11〕AREVALO J F，FROMOW-GUERRA J，QUIROZ-MERE?
ADO H，et al. Primary intravitreal bevaeizumab（Avastin）
for diabetic macular edema：results from the Pan-Ameri?
can Collaborative Retina Study Group at 6-month fol?
low-up〔J〕. Ophthalmology，2007，114：743-750.
〔12〕SOLIMAN W，VINTEN M，SANDER B，et al. Optical co?
herence tomography and vessel diameter changes after in?
travitreal bevacizumab in diabetic macular edema〔J〕. Ae?
ta Ophthalmol Scand，2007，85：765-771.
〔13〕HARITOGLOU C，KOOK D，NEUBAUER A，et al. Intra?
vitreal bevacizumab（Avastin）therapy for persistent diffuse
diabetic macular edema〔J〕. Retina，2006，26：999-1005.
〔14〕段直光，贾云琴，莫逆，等. Bevacizumab治疗视网膜静
脉阻塞继发黄斑水肿的临床观察〔J〕. 国际眼科杂志，
2014，14（9）：1594-1598.
〔15〕CHAN A，DUKER J S. A standardized method for report?
ing changes in macular thickening using optical coherence
tomography〔J〕. Arch Ophthalmol，2005，123：939-943.